# Barry M. Brenner

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/barry-m-brenner/

## Facts

| Field | Value |
| --- | --- |
| Citations | 61,380 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 109 |
| i10-index | 274 |
| OpenAlex ID | https://openalex.org/A5016263167 |
| Works | 377 |

## Researcher papers

- [Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/effects-of-losartan-on-renal-and-cardiovascular-outcomes-in-patients-with-type-2/)
- [Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy/)
- [Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes](https://scholariq.org/papers/cardiorenal-end-points-in-a-trial-of-aliskiren-for-type-2-diabetes/)
- [Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis](https://scholariq.org/papers/pharmacological-blood-pressure-lowering-for-primary-and-secondary-prevention-of/)
- [Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL](https://scholariq.org/papers/proteinuria-a-target-for-renoprotection-in-patients-with-type-2-diabetic/)
- [Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy](https://scholariq.org/papers/albuminuria-a-therapeutic-target-for-cardiovascular-protection-in-type-2/)
- [The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study](https://scholariq.org/papers/the-risk-of-developing-end-stage-renal-disease-in-patients-with-type-2-diabetes/)
- [Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials](https://scholariq.org/papers/change-in-albuminuria-as-a-surrogate-endpoint-for-progression-of-kidney-disease/)
- [Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis](https://scholariq.org/papers/age-stratified-and-blood-pressure-stratified-effects-of-blood-pressure-lowering/)
- [Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis](https://scholariq.org/papers/serum-potassium-and-adverse-outcomes-across-the-range-of-kidney-function-a-ckd/)
- [Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies](https://scholariq.org/papers/change-in-albuminuria-and-subsequent-risk-of-end-stage-kidney-disease-an/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Renin-Angiotensin System Studies](https://scholariq.org/topics/renin-angiotensin-system-studies/)
- [Birth, Development, and Health](https://scholariq.org/topics/birth-development-and-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.